DLL3 Polyclonal antibody
DLL3 Polyclonal Antibody for WB, IHC, IF-P, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IHC, IF-P, ELISA
Conjugate
Unconjugated
Cat no : 25535-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | mouse liver tissue, rat brain tissue |
| Positive IHC detected in | human liver tissue, mouse brain tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | mouse brain tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 1 publications below |
| IHC | See 2 publications below |
Product Information
25535-1-AP targets DLL3 in WB, IHC, IF-P, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | DLL3 fusion protein Ag21965 相同性解析による交差性が予測される生物種 |
| Full Name | delta-like 3 (Drosophila) |
| Calculated molecular weight | 65 kDa |
| Observed molecular weight | 65-70 kDa |
| GenBank accession number | BC000218 |
| Gene symbol | DLL3 |
| Gene ID (NCBI) | 10683 |
| RRID | AB_2880122 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
The Delta-Notch pathway is an evolutionarily conserved signaling pathway which controls a broad range of developmental processes including cell fate determination, terminal differentiation and proliferation (PMID: 22353464). In mammals, four Notch receptors (NOTCH1-4) and five activating canonical ligands (JAGGED1, JAGGED2, DLL1, DLL3 and DLL4) have been described (PMID: 22353464). DLL3 is an inhibitory ligand of the Notch signaling pathway that is predominantly localizes to the Golgi apparatus (PMID: 17664336) in normal condition. Normal tissue expression of DLL3 is highest in fetal brain, and DLL3 plays a key role in somitogenesis in the paraxial mesoderm (PMID: 26311731). It has been reported that DLL3 is expressed on the surface of tumor cells of small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas (LCNEC) and has emerged as a novel therapeutic target (PMID: 26311731; 28487384).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for DLL3 antibody 25535-1-AP | Download protocol |
| IHC protocol for DLL3 antibody 25535-1-AP | Download protocol |
| IF protocol for DLL3 antibody 25535-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Transl Oncol High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients. | ||
Technol Cancer Res Treat Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis. | ||
J Immunother Cancer Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. |
